United States securities and exchange commission logo





                              May 28, 2021

       David Campbell, Ph.D.
       Chief Executive Officer
       Janux Therapeutics, Inc.
       11099 N. Torrey Pines Road, Suite 290
       La Jolla, CA 92037

                                                        Re: Janux Therapeutics,
Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed May 19, 2021
                                                            File No. 333-256297

       Dear Dr. Campbell:

              We have reviewed your registration statement and have the
following comments. In
       some of our comments, we may ask you to provide us with information so
we may better
       understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Registration Statement on Form S-1 filed May 19, 2021

       Business
       License Agreement with WuXi Biologics (Hong Kong) Limited, page 135

   1.                                                   We note your revised
disclosure that you have obtained a license to use the WuXi
                                                        Biologics Licensed
Technology to make, use, sell, offer for sale and import certain
                                                        therapeutic products.
Please revise to explain the nature of the therapeutic products and
                                                        how it relates to your
product candidates.
   2.                                                   Please revise to
specify the royalty term if you do not buy out your remaining royalty
                                                        obligations.
 David Campbell, Ph.D.
Janux Therapeutics, Inc.
May 28, 2021
Page 2



        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       You may contact Tracie Mariner at 202-551-3744 or Al Pavot at
202-551-3738 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Deanna Virginio at 202-551-4530 or Irene Paik at 202-551-6553 with any
other
questions.



                                                           Sincerely,
FirstName LastNameDavid Campbell, Ph.D.
                                                           Division of
Corporation Finance
Comapany NameJanux Therapeutics, Inc.
                                                           Office of Life
Sciences
May 28, 2021 Page 2
cc:       Ken Rollins, Esq.
FirstName LastName